Jorey Chernett, a reported ten percent owner of Oncology Institute, Inc. (NASDAQ: TOI), executed multiple purchases of the company’s common stock in mid-March 2026 that together totaled $1,225,100, according to a Form 4 filing with the Securities and Exchange Commission.
The acquisitions took place over three days. On March 13, 2026, Chernett acquired 263,000 shares at an average price of $2.92 per share; individual transactions that day ranged from $2.77 to $3.34 per share. On March 16, 2026, Chernett added 60,985 shares at $3.29 per share, with transaction prices between $3.25 and $3.43. The final tranche was purchased on March 17, 2026, consisting of 75,000 shares at $3.42 per share, in transactions that ranged from $3.39 to $3.49.
Following the March transactions, Chernett directly holds 10,251,929 shares of Oncology Institute, Inc. At the time of the filing, TOI shares were trading at $3.59, after a 412% advance over the past year.
The insider activity occurred in the wake of the company’s fourth-quarter 2025 financial report, which exceeded analyst expectations. Oncology Institute posted an earnings per share of -$0.06 for the quarter versus the forecasted -$0.09, a positive surprise of 33.33%. Revenue for the quarter was $141.96 million, topping the anticipated $139.79 million. The earnings release was met with positive aftermarket trading activity, reflecting investor reception to the results.
Market valuation commentary included in the reporting indicates that, based on InvestingPro analysis, Oncology Institute appears slightly overvalued at prevailing share prices relative to its Fair Value estimate.
Context and implications
The Form 4 disclosure documents the timing and size of the purchases without offering commentary from the insider. The sequence of transactions - spanning March 13, 16 and 17, 2026 - and the specific price ranges for each day are detailed in the filing and are reflected above.
The reported financial results for Q4 2025 and the insider purchases are contemporaneous facts presented in public filings and company reporting. The InvestingPro assessment that the stock is slightly overvalued is noted as part of the available market analysis.
Data sources cited in filings
- SEC Form 4 disclosure of insider transactions
- Company Q4 2025 financial results
- InvestingPro Fair Value analysis referenced in disclosures